This was followed by active clinical development for the treatment of several autoimmune diseases, and the first indication for which efgartigimod entered late-stage clinical trials was gMG, which was found to be ameliorated by intravenous (i.v.) delivery of efgartigimod in a pivotal, proof-of-concept, phase II study in 2019 [227]
364 Inducer specificity by CsoR-family repressors was originally described in the context of a simple W-X-Y-Z motif using the Mt CsoR Cu I chelate as a template, 203 where the first coordination shell ligands around a subunit-bridging, trigonally coordinated Cu I define the X (Cys36), Y (His61) and Z (Cys65) residue positions (Figure 12B)
Our BPC-157 10mg is commonly used in research involving: Cellular signaling pathways Tissue remodeling and repair mechanisms Extracellular matrix regulation Molecular biology and biochemical studies All products are intended for research use only and are not for human or animal consumption, therapeutic use, or clinical application
Yao, Z., Yang, W., Gao, Z